Engineered immune cells take on Hard-to-Treat breast cancers
NCT ID NCT07486089
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment using specially engineered immune cells (CAR-NK cells) to fight advanced breast cancer, including HER2-positive and triple-negative types. About 60 adults whose cancer has not responded to standard treatments will receive cells tailored to their tumor's markers. The goal is to control the disease and reduce side effects, but this is not a cure—patients may need ongoing care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER (LOCALLY ADVANCED OR METASTATIC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a Custom-Made vaccine outsmart Triple-Negative breast cancer?
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can a drug combo outsmart a tough breast cancer subtype?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a new drug combo outsmart triple-negative breast cancer?